Management of fingolimod in clinical practice

Clinical Neurology and Neurosurgery

Volumn 115, Issue SUPPL.1, 2013, Pages

  Thomas, Katja ^a   Ziemssen, Tjalf ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Clinical management; Clinical practice; Multiple sclerosis; Registry; Safety

Indexed keywords

FINGOLIMOD; GLUCOCORTICOID; LIVER ENZYME; NATALIZUMAB; PLACEBO;

ALGORITHM; ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HERPES SIMPLEX ENCEPHALITIS; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HYPERTENSION; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTOPENIA; MEDICAL DOCUMENTATION; MULTIPLE SCLEROSIS; REGISTER; RETINA MACULA EDEMA; SIDE EFFECT;

CLINICAL MANAGEMENT; CLINICAL PRACTICE; MULTIPLE SCLEROSIS; REGISTRY; SAFETY;

ADMINISTRATION, ORAL; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; RECURRENCE; SPHINGOSINE;

EID: 84890029999     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2013.09.023     Document Type: Article

References (19)

1. K. Adachi, and K. Chiba FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology Perspectives in Medicinal Chemistry 1 2008 11 23
2. L. Kappos, E.W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, and P. Calabresi A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis New England Journal of Medicine 362 2010 387 401
3. J.A. Cohen, F. Barkhof, G. Comi, H.P. Hartung, B.O. Khatri, and X. Montalban Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis New England Journal of Medicine 362 2010 402 415
4. T. Baumruker, A. Billich, and V. Brinkmann FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis Expert Opinion on Investigational Drugs 16 2007 283 289
5. J. Chun, and H.P. Hartung Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clinical Neuropharmacology 33 2010 91 101
6. D.R. Jeffery, C.E. Markowitz, A.T. Reder, B. Weinstock-Guttman, and K. Tobias Fingolimod for the treatment of relapsing multiple sclerosis Expert Review of Neurotherapeutics 11 2011 165 183
7. M. Mehling, L. Kappos, and T. Derfuss Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions Current Neurology and Neuroscience Reports 11 2011 492 497
8. A. Laroni, D. Brogi, V. Milesi, L. Abate, A. Uccelli, and G. Mancardi Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption Multiple Sclerosis 19 2012 1236 1237
9. J. Havla, B. Tackenberg, K. Hellwig, I. Meinl, M. Krumbholz, and F. Seitz Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis Journal of Neurology 260 2012 1382 1387
10. K. Budde, M. Schutz, P. Glander, H. Peters, J. Waiser, and L. Liefeldt FTY720 (fingolimod) in renal transplantation Clinical Transplantation 20 Suppl. 17 2006 17 24
11. J.M. Kovarik, S. Hartmann, M. Bartlett, G.J. Riviere, D. Neddermann, and Y. Wang Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects Biopharmaceutics & Drug Disposition 28 2007 97 104
12. A. Horga, J. Castillo, and X. Montalban Fingolimod for relapsing multiple sclerosis: an update Expert Opinion on Pharmacotherapy 11 2010 1183 1196
13. M. Mehling, V. Brinkmann, J. Antel, A. Bar-Or, N. Goebels, and C. Vedrine FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis Neurology 71 2008 1261 1267
14. T.A. Johnson, Y. Lapierre, A. Bar-Or, and J.P. Antel Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis Archives of Neurology 67 2010 1449 1455
15. A. Winkelmann, M. Loebermann, E.C. Reisinger, H.P. Hartung, and U.K. Zettl Fingolimod treatment for multiple sclerosis patients What do we do with varicella? Annals of Neurology 70 2011 673 674 [author reply 674]
16. N. Jain, and M.T. Bhatti Fingolimod-associated macular edema: incidence, detection, and management Neurology 78 2012 672 680
17. T. Ziemssen, T. van Lokven, R. Kempke, and M. Meergans Study design and first results of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya (R)) in multiple sclerosis patients in Germany (PANGAEA) Neurology 2012 78
18. T. Ziemssen, T. van Lokven, R. Kempcke, and M. Meergans Study design and first results of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya (R)) in multiple sclerosis patients in Germany (PANGAEA) Journal of Neurology 259 2012 S72
19. T. Ziemssen, R. Kempcke, M. Eulitz, L. Großmann, A. Suhrbier, and K. Thomas Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients Journal of Neural Transmission 120 Suppl (1) 2013 61 66